UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

European journal of cancer (1990), 2014-03, Vol.50 (4), p.706-712

2014

Volltextzugriff (PDF)

Drug resistance and its significance for treatment decisions in non-small-cell lung cancer

Current oncology (Toronto), 2012-06, Vol.19 (Suppl 1), p.S45-51

2012

Volltextzugriff (PDF)

The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials

Journal of thrombosis and haemostasis, 2007-04, Vol.5 (4), p.729-737

2007

Volltextzugriff (PDF)

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

Current oncology (Toronto), 2018-08, Vol.25 (4), p.e291-297

2018

Volltextzugriff (PDF)

Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy

Current oncology (Toronto), 2016-12, Vol.23 (6), p.386-390

2016

Volltextzugriff (PDF)

Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

Annals of oncology, 2018-10, Vol.29, p.viii521-viii521

2018

Volltextzugriff (PDF)

Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2006-06, Vol.52 (3), p.327-332

2006

Volltextzugriff (PDF)

A retrospective review of cancer treatments and outcomes among Inuit referred from Nunavut, Canada

Current oncology (Toronto), 2015-08, Vol.22 (4), p.246-251

2015

Volltextzugriff (PDF)

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors

Investigational new drugs, 2015-04, Vol.33 (2), p.321-331

2015

Volltextzugriff (PDF)

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19

Journal of clinical oncology, 2010-06, Vol.28 (18_suppl), p.LBA7005-LBA7005

2010

Volltextzugriff (PDF)

1442PAfatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non‐Hodgkin's lymphoma

American journal of hematology, 1998-10, Vol.59 (2), p.156-160

1998

Volltextzugriff (PDF)

Physiological and Clinical Aspects of Vitamin A and Its Metabolites

Critical reviews in clinical laboratory sciences, 1992, Vol.29 (3-4), p.185-215

1992

Volltextzugriff (PDF)

Combination chemotherapy with teniposide (VM26) and carboplatin in small cell lung cancer

American journal of clinical oncology, 1993-08, Vol.16 (4), p.295-300

1993

Volltextzugriff (PDF)

Distraction-flexion injury in a neurologically intact pediatric patient treated nonoperatively: Case study

Spine (Philadelphia, Pa. 1976), 2001-09, Vol.26 (17), p.1932-1935

2001

Volltextzugriff (PDF)

Activating transcription factor 3 (ATF3) as a potential biomarker of platinum sensitivity in non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e21012-e21012

2011

Volltextzugriff (PDF)

ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib

MD conference express, 2015-05, Vol.15 (8), p.5-6

2015

Volltextzugriff (PDF)

Acute megakaryoblastic leukaemia with 3q inversion and elevated thrombopoietin (TSF): an autocrine role for TSF?

British journal of haematology, 1985-12, Vol.61 (4), p.687-694

1985

Volltextzugriff (PDF)

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): A first-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent dosed once daily on days 1, 2, 3, and 4 of a 21-day cycle

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13005-e13005

2010

Volltextzugriff (PDF)

Angiogenic factors and soluble receptors in NCIC CTG BR.24

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3047-3047

2011

Volltextzugriff (PDF)

TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.11023-11023

2009

Volltextzugriff (PDF)

Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7590-7590

2010

Volltextzugriff (PDF)

L-BLP25 treatment for advanced non-small cell lung cancer (NSCLC): Safety data from a phase IIb trial compared with an integrated safety analysis (ISA)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13058-e13058

2010

Volltextzugriff (PDF)

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8009-8009

2009

Volltextzugriff (PDF)

The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8075-8075

2009

Volltextzugriff (PDF)

1 – 25 von 760

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(691)
Mit Volltextzugriff
(662)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(750)
Deutsch
(6)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(462)
Life Sciences & Biomedicine
(356)
Humans
(235)
Biological And Medical Sciences
(173)
Female
(156)
Male
(145)
Medical Sciences
(109)
Adult
(105)
Middle Aged
(94)
Physical Sciences
(85)
Animals
(83)
Fundamental And Applied Biological Sciences. Psychology
(71)
Oncology
(62)
Aged
(61)
Environmental Sciences & Ecology
(44)
Technology
(42)
Adolescent
(40)
Surgery
(36)
Astronomy & Astrophysics
(35)
Child
(35)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

Drug resistance and its significance for treatment decisions in non-small-cell lung cancer

The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy

Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer

A retrospective review of cancer treatments and outcomes among Inuit referred from Nunavut, Canada

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19

1442PAfatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial

Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non‐Hodgkin's lymphoma

Physiological and Clinical Aspects of Vitamin A and Its Metabolites

Combination chemotherapy with teniposide (VM26) and carboplatin in small cell lung cancer

Distraction-flexion injury in a neurologically intact pediatric patient treated nonoperatively: Case study

Activating transcription factor 3 (ATF3) as a potential biomarker of platinum sensitivity in non-small cell lung cancer (NSCLC)

ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib

Acute megakaryoblastic leukaemia with 3q inversion and elevated thrombopoietin (TSF): an autocrine role for TSF?

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): A first-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent dosed once daily on days 1, 2, 3, and 4 of a 21-day cycle

Angiogenic factors and soluble receptors in NCIC CTG BR.24

TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21

Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results

L-BLP25 treatment for advanced non-small cell lung cancer (NSCLC): Safety data from a phase IIb trial compared with an integrated safety analysis (ISA)

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)

The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC)

Suchergebnisse filtern